Study identifier:D4300C00027
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers
Healthy
Phase 1
Yes
Fostamatinib
Male
10
Interventional
18 Years - 55 Years
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Jan 2014 by AstraZeneca
AstraZeneca
-
Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer dose.
A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers.
Location
Location
RUDDINGTON, NOTTINGHAM, United Kingdom
Location
Ruddington, NOTTINGHAM, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: Fostamatinib 50 mg tablet | Drug: Fostamatinib Fostamatinib 50 mg tablet |
Experimental: Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose | Drug: Fostamatinib Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.